Key Points
- Professor Peter Hindmarsh was barred from treating patients by University College London Hospitals in March 2023 during Lucy Letby’s trial.
- His evidence supported the prosecution’s claim that two babies were poisoned with insulin.
- The hospital raised concerns about advice given to children and families, including insulin-related cases.
- A medical tribunal did not suspend his registration but ordered direct supervision of his clinical work.
- The jury was not told about the restriction during the trial.
Manchester (North London News) November 18, 2026 – Professor Peter Hindmarsh, the paediatric endocrinologist whose evidence helped prosecutors argue that Lucy Letby poisoned two babies with insulin, was barred from treating patients during her trial over concerns about patient safety. University College London Hospitals imposed the restriction in March 2023, five months before the trial concluded. The development was not disclosed to the jury, according to reports attributed to The Guardian’s investigation.
Why was Professor Peter Hindmarsh barred from treating patients?
As reported by The Guardian and summarised by Cardiff Daily, University College London Hospitals medical director Dr Tim Hodgson told the General Medical Council that the trust could not accept the level of risk Professor Hindmarsh appeared to pose to children and young people, even under close supervision.
The concerns included advice involving insulin. In two cases, Professor Hindmarsh allegedly advised families to stop administering insulin to children at home. One child subsequently experienced diabetic ketoacidosis, a potentially life-threatening complication associated with severe insulin deficiency.
What was Professor Peter Hindmarsh’s role in the Lucy Letby trial?
Professor Hindmarsh gave evidence for the prosecution at Manchester Crown Court. His testimony supported the argument that Letby had injected insulin into intravenous fluid bags given to babies at the Countess of Chester Hospital.
Reports stated that Letby’s defence knew about a General Medical Council investigation into Professor Hindmarsh’s fitness to practise, but was not informed that University College London Hospitals had barred him from clinical work or that a tribunal had tightened supervision requirements.
What did the medical tribunal decide?
In April 2023, a three-person medical practitioners tribunal declined to suspend Professor Hindmarsh’s registration, finding that suspension would be disproportionate. The tribunal nevertheless identified patient-safety concerns in three cases and ordered that he be directly supervised when treating patients.
The order had limited practical effect because University College London Hospitals had already excluded him from clinical practice. The tribunal allowed him to continue non-clinical work, including acting as an expert witness.
What could the development mean for the Lucy Letby case?
The disclosure may prompt scrutiny of how information about expert witnesses’ clinical restrictions and regulatory investigations is shared during criminal trials. It does not, by itself, establish that Professor Hindmarsh’s evidence was inaccurate or determine whether Lucy Letby’s convictions are affected.
Any legal consequences would depend on applications by the defence, decisions by the courts and assessments of whether the undisclosed information was relevant to the reliability or admissibility of the evidence. The available reports do not state that the convictions have been overturned or that a court has ordered a retrial.
Background to the development
Lucy Letby was convicted after a trial concerning the deaths of seven babies and attempts to murder seven others. Professor Hindmarsh’s evidence focused on medical findings that prosecutors said were consistent with deliberate insulin poisoning. University College London Hospitals restricted his clinical work while the trial was continuing. The General Medical Council proceedings resulted in direct-supervision requirements rather than suspension of his registration.
What may happen next?
The disclosure is likely to lead to questions about the handling of expert-witness information by prosecutors, defence teams and courts. Lawyers may examine whether the restriction should have been disclosed to the defence or considered by the trial judge. Regulators and medical institutions may also face scrutiny over how patient-safety restrictions involving expert witnesses are communicated. No confirmed outcome has been reported showing that Professor Hindmarsh’s evidence or Letby’s convictions has been legally set aside.
